|
Sobetirome
|
DB07425 |
|
|
(R)-TRANS-4-(1-AMINOETHYL)-N-(4-PYRIDYL) CYCLOHEXANECARBOXAMIDE
|
DB08756 |
|
|
5-(2-chlorophenyl)furan-2-carbohydrazide
|
DB08757 |
|
|
[1-HYDROXY-2-(1,1'_3',1''-TERPHENYL-3-YLOXY)ETHANE-1,1-DIYL]BIS(PHOSPHONIC ACID)
|
DB07426 |
|
|
2-[(2-methoxy-5-methylphenoxy)methyl]pyridine
|
DB07427 |
|
|
IMIDAZO[2,1-A]ISOQUINOLINE-2-CARBOHYDRAZIDE
|
DB08758 |
|
|
4-[(5-methoxy-2-methylphenoxy)methyl]pyridine
|
DB07428 |
|
|
[(3R,4S,5S,7R)-4,8-DIHYDROXY-3,5,7-TRIMETHYL-2-OXOOCTYL]PHOSPHONIC ACID
|
DB08759 |
|
|
2-({[4-bromo-3-(diethylsulfamoyl)phenyl]carbonyl}amino)benzoic acid
|
DB07429 |
|
|
1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE
|
DB08750 |
|
|
(1R)-4-(3-phenoxyphenyl)-1-phosphonobutane-1-sulfonic acid
|
DB07420 |
|
|
N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
|
DB08751 |
|
|
4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile
|
DB07421 |
|
|
N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide
|
DB08752 |
|
|
(2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide
|
DB07422 |
|
|
4-{(1E)-3-OXO-3-[(2-PHENYLETHYL)AMINO]PROP-1-EN-1-YL}-1,2-PHENYLENE DIACETATE
|
DB08753 |
|
|
6-HYDROXY-1,3-BENZOTHIAZOLE-2-SULFONAMIDE
|
DB08765 |
|
|
HONH-BENZYLMALONYL-L-ALANYLGLYCINE-P-NITROANILIDE
|
DB07434 |
|
|
IMC-1C11
|
DB06101 |
[IMC-1C11 is an anti-angiogenesis agent. It is a chimeric anti-kinase insert domain-containing receptor (KDR) antibody that blocks VEGFR-KDR interaction and inhibits VEGFR-induced endothelial cell proliferation. IMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.] |
|
1,2,3-TRIHYDROXY-1,2,3,4-TETRAHYDROBENZO[A]PYRENE
|
DB07435 |
|
